Fig. 1: Characterisation of reported secondary malignancies of T-cell origin after CAR T-cell therapy. | Gene Therapy

Fig. 1: Characterisation of reported secondary malignancies of T-cell origin after CAR T-cell therapy.

From: Secondary malignancy of T-cell origin after CAR T-cell therapy: EMA’s conclusions from the evaluation of 38 suspected cases

Fig. 1: Characterisation of reported secondary malignancies of T-cell origin after CAR T-cell therapy.

A Number of secondary malignancies of T-cell origin following CAR T-cell therapy reported per year up to 11 April 2024. B MedDRA preferred terms reported for malignancies of T-cell origin. C Time-to-onset (TTO) for malignancies of T-cell origin after CAR T-cell therapy in months. TTO was unknown in three out of 38 cases.

Back to article page